Xylogenics Revenue and Competitors
Estimated Revenue & Valuation
- Xylogenics's estimated annual revenue is currently $1.4M per year.
- Xylogenics's estimated revenue per employee is $155,000
Employee Data
- Xylogenics has 9 Employees.
- Xylogenics grew their employee count by 0% last year.
Xylogenics's People
Name | Title | Email/Phone |
---|---|---|
1 | scientist; founder | Reveal Email/Phone |
2 | VP Operations | Reveal Email/Phone |
3 | Director Metabolic Engineering | Reveal Email/Phone |
4 | National Sales Manager | Reveal Email/Phone |
Xylogenics Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $0.8M | 5 | -17% | N/A | N/A |
#2 | $5.7M | 37 | 6% | N/A | N/A |
#3 | $10.2M | 66 | 6% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $2M | 13 | 0% | N/A | N/A |
#6 | $7.6M | 49 | -2% | N/A | N/A |
#7 | $0.8M | 5 | -17% | N/A | N/A |
#8 | $7.9M | 51 | 6% | N/A | N/A |
#9 | $37.7M | 243 | -2% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is Xylogenics?
Xylogenics is a biotechnology company incorporated in 2008 to provide innovative product solutions utilizing the many benefits of modified yeast microorganisms. Our corporate vision and business objective is to utilize our expertise in engineering yeast to synthesize commercial chemicals from a wide portfolio of renewable environmentally friendly feed stocks. Our first commercial product, known as “SYMMETRRYâ€, will be launched in 2016 and will produce ethanol more cost effectively in the 200+ starch ethanol production plants in the United States. In addition to pursuing the SYMMETRRY line, we are also pursuing negotiations for services and strategic partnerships with multiple industry leaders.
keywords:N/AN/A
Total Funding
9
Number of Employees
$1.4M
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $0.7M | 9 | -10% | N/A |
#2 | N/A | 28 | 33% | N/A |
#3 | $3.7M | 29 | 4% | N/A |
#4 | $7.2M | 31 | 0% | N/A |
#5 | N/A | 34 | 17% | N/A |